0000899243-19-002323.txt : 20190201
0000899243-19-002323.hdr.sgml : 20190201
20190201163848
ACCESSION NUMBER: 0000899243-19-002323
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190131
FILED AS OF DATE: 20190201
DATE AS OF CHANGE: 20190201
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Shannon John Patrick Jr
CENTRAL INDEX KEY: 0001553595
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38536
FILM NUMBER: 19560299
MAIL ADDRESS:
STREET 1: DURATA THERAPEUTICS, INC.
STREET 2: 89 HEADQUARTERS PLAZA NORTH, 14TH FLOOR
CITY: MORRISTOWN
STATE: NJ
ZIP: 07960
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: XERIS PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001346302
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 203352427
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 180 NORTH LASALLE STREET
STREET 2: STE 1800
CITY: CHICAGO
STATE: IL
ZIP: 60601
BUSINESS PHONE: 512-498-2670
MAIL ADDRESS:
STREET 1: 180 NORTH LASALLE STREET
STREET 2: STE 1800
CITY: CHICAGO
STATE: IL
ZIP: 60601
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-01-31
0
0001346302
XERIS PHARMACEUTICALS INC
XERS
0001553595
Shannon John Patrick Jr
C/O XERIS PHARMACEUTICALS, INC.
180 N. LASALLE STREET, SUITE 1810
CHICAGO
IL
60601
0
1
0
0
See Remarks
Stock Option (right to buy)
13.88
2019-01-31
4
A
0
80000
0.00
A
2029-01-31
Common Stock
80000
80000
D
25% of these shares shall vest on the first anniversary of the vesting commencement date, with the remainder vesting ratably over the following 36 months.
Executive Vice President and Chief Operating Officer
/s/ Beth Hecht, as Attorney-in-Fact
2019-02-01